

## United States Patient and Trademark Office to the control of the c

United States Patent and Trademark. Office
Address: COMMISSIONER/FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/375,333	08/16/1999	HERMANN OPPERMANN	STK-075	4896
21323	7590 10/07/2003		EXAMI	NER
,	RWITZ & THIBEAUL	T, LLP	ROMEO, D	DAVID S
HIGH STREE			ART UNIT	PAPER NUMBER
BOSTON, M			1647	
·			DATE MAILED: 10/07/2003	, 15

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DI RTMENT OF COMMERCE U.S. Patent and Tratemark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO./	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	

EXAMINER

ART UNIT PAPER

15

DATE MAILED:


Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents** 

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

David S Romeo
Primary Examiner
Art Unit: 1647



	F	II F	COPY
Application No.	Applicant(s)		י ויטט
09/375,333	OPPERMANN B	ET AL.	
Examiner	 Art Unit		
David S Romeo	1647		

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requiremer	ıts
for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):	

for suc	th a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
	☑1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	☐2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	☑4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	☐5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	☐6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	□7. Other:
Applica	ant Must Provide:
	A substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	☑ A statement that the content of the paper and computer readable copies are the same and, where applicable,
	include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For que	
For Ru For CR	include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

**PLEAS**